Clinical Trial

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
Trial Details
NCT Number NCT07117474
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Subjects With Mild Hypertension
Enrollment 60 participants
Start Date 2024-12-24
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-12